Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says
The study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer’s patients who take the therapy get worse after they stop treatment.
The study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer’s patients who take the therapy get worse after they stop treatment.